BIOLINERX LTD/S (NASDAQ:BLRX) shares saw unusually-high trading volume on Wednesday . Approximately 1,313,818 shares changed hands during trading, an increase of 6% from the previous session’s volume of 1,234,306 shares.The stock last traded at $0.38 and had previously closed at $0.35.
BLRX has been the topic of several recent research reports. Maxim Group set a $2.00 price target on shares of BIOLINERX LTD/S and gave the company a “buy” rating in a research report on Thursday, March 28th. Oppenheimer reissued a “buy” rating on shares of BIOLINERX LTD/S in a research report on Tuesday, March 19th. HC Wainwright set a $3.00 price target on shares of BIOLINERX LTD/S and gave the company a “buy” rating in a research report on Thursday, March 28th. Finally, Zacks Investment Research upgraded shares of BIOLINERX LTD/S from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a report on Monday, April 1st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $2.13.
The firm has a market cap of $40.26 million, a PE ratio of -1.80 and a beta of 1.63. The company has a current ratio of 5.12, a quick ratio of 4.74 and a debt-to-equity ratio of 0.18.
BIOLINERX LTD/S (NASDAQ:BLRX) last issued its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). As a group, analysts forecast that BIOLINERX LTD/S will post -0.17 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. ETF Managers Group LLC increased its stake in BIOLINERX LTD/S by 79.4% during the fourth quarter. ETF Managers Group LLC now owns 375,909 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 166,386 shares during the period. Menta Capital LLC purchased a new stake in BIOLINERX LTD/S during the fourth quarter worth about $33,000. Delek Group Ltd. purchased a new stake in BIOLINERX LTD/S during the first quarter worth about $92,000. Deutsche Bank AG purchased a new stake in BIOLINERX LTD/S during the fourth quarter worth about $26,000. Finally, Two Sigma Securities LLC purchased a new stake in BIOLINERX LTD/S during the fourth quarter worth about $25,000. Hedge funds and other institutional investors own 33.72% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “BIOLINERX LTD/S (BLRX) Sees Unusually-High Trading Volume” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2019/05/22/biolinerx-ltd-s-blrx-sees-unusually-high-trading-volume.html.
About BIOLINERX LTD/S (NASDAQ:BLRX)
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Read More: What does the Dow Jones Industrial Average (DJIA) measure?
Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.